Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCLL9718S in Relapsed/Refractory or Treatment-Naive AML
NCT03298516Phase 1Completed
- Sponsor
- Genentech
- Start
- Nov 2017
- Primary completion
- Jul 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of DCLL9718A in acute myeloid leukemia (AML) (2 arms), sponsored by Genentech. Primary endpoints: Percentage of participants With Adverse Events (AEs) up to 3 years, Percentage of Participants With Dose-Limiting Toxicities and 2 more. Started Nov 2017; status: completed.
02
Drugs
DCLL9718A
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03298516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03298516.